| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dineshree V Naiker, Stanley V Catts, Vibeke S Catts, Kuldip S Bedi, Lesley J Bryan-Lluk. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. European journal of pharmacology. vol 540. issue 1-3. 2006-12-11. PMID:16730699. |
the purpose of the present study was to determine antipsychotic doses that achieve 80% striatal dopamine d2-receptor occupancy for haloperidol, risperidone and olanzapine in rats. |
2006-12-11 |
2023-08-12 |
rat |
| Dineshree V Naiker, Stanley V Catts, Vibeke S Catts, Kuldip S Bedi, Lesley J Bryan-Lluk. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. European journal of pharmacology. vol 540. issue 1-3. 2006-12-11. PMID:16730699. |
the doses required to achieve dopamine d2-receptor occupancy of 80% in 11- and 24-week old rats were: haloperidol 0.25 mg/kg/day, risperidone 5 mg/kg/day and olanzapine 10 mg/kg/day. |
2006-12-11 |
2023-08-12 |
rat |
| Taylor Moran-Gates, Carla Massari, Amaury Graulich, Jean-François Liégeois, Frank I Taraz. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. Journal of neuroscience research. vol 84. issue 3. 2006-11-01. PMID:16810690. |
changes in dopamine (da) d(1), d(2), d(3), and d(4) receptors and serotonin 5-ht(1a) and 5-ht(2a) receptors in rat forebrain regions were autoradiographically quantified after continuous infusion of jl 13 [(5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine fumarate] for 28 days with osmotic minipumps and compared with the effects of other typical (fluphenazine) and atypical (clozapine, olanzapine, and risperidone) antipsychotic drugs from previous studies. |
2006-11-01 |
2023-08-12 |
rat |
| J J Mateos, F Lomeña, E Parellada, M Font, E Fernández, J Pavia, A Prats, M Bernard. [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone]. Revista espanola de medicina nuclear. vol 25. issue 3. 2006-10-17. PMID:16762269. |
[striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone]. |
2006-10-17 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Cheng-Chun Lee, Yi-Ching Liu, Wen-Ho Chan. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics. vol 6. issue 2. 2006-09-28. PMID:15882132. |
the dopamine d2 receptor (drd2) ser311cys polymorphism may also play a role in determining risperidone efficacy for positive, negative and cognitive symptoms, the drd2 ins-a2/del-a1 diplotype may predict better risperidone response, and the drd3 ser311cys variant may affect general treatment response of several atypical agents. |
2006-09-28 |
2023-08-12 |
Not clear |
| Philip J Tyson, Keith R Laws, Kenneth A Flowers, Agi Tyson, Ann M Mortime. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry and clinical neurosciences. vol 60. issue 4. 2006-09-20. PMID:16884450. |
comparisons were done for matched schizophrenia patients who were on antipsychotics with (i) an affinity for multiple receptors (olanzapine, clozapine, quetiapine) versus those that have preferential affinity for dopamine receptors (risperidone, amisulpride); and patients on medication with (ii) a high affinity for serotonin (5ht-2a) receptors (risperidone, olanzapine, clozapine) versus those with a low (or no) affinity for 5ht-2a receptors (quetiapine, amisulpride). |
2006-09-20 |
2023-08-12 |
Not clear |
| Jiri Horacek, Vera Bubenikova-Valesova, Milan Kopecek, Tomas Palenicek, Colleen Dockery, Pavel Mohr, Cyril Hösch. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS drugs. vol 20. issue 5. 2006-08-04. PMID:16696579. |
by olanzapine and risperidone), partial d(2) receptor antagonism or the preferential blockade of inhibitory dopamine autoreceptors. |
2006-08-04 |
2023-08-12 |
Not clear |
| Elizabeth A Pehek, Christine Nocjar, Bryan L Roth, Tara A Byrd, Omar S Mabrou. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 2. 2006-07-06. PMID:15999145. |
cortical perfusion with m100907, or the atypical antipsychotic drug risperidone, but not the 5-ht2b/c ligand sb 206553, also decreased dopamine release induced physiologically by stress. |
2006-07-06 |
2023-08-12 |
rat |
| Gary Remington, David Mamo, Alain Labelle, Jeffrey Reiss, Chekkera Shammi, Erik Mannaert, Steve Mann, Shitij Kapu. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. The American journal of psychiatry. vol 163. issue 3. 2006-04-25. PMID:16513859. |
a pet study evaluating dopamine d2 receptor occupancy for long-acting injectable risperidone. |
2006-04-25 |
2023-08-12 |
Not clear |
| Zhu Li, Junji Ichikawa, Mei Huang, Adam J Prus, Jin Dai, Herbert Y Meltze. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology. vol 183. issue 2. 2006-04-13. PMID:16220333. |
atypical antipsychotic drugs (apds) such as clozapine, olanzapine, quetiapine, risperidone, and ziprasidone are serotonin (5-ht)(2a) antagonists and relatively weaker dopamine (da) d(2) antagonists, with variable 5-ht(2c) antagonist properties. |
2006-04-13 |
2023-08-12 |
rat |
| Boong-Nyun Kim, Chung-Bum Lee, Jun-Won Hwang, Min-Sub Shin, Soo-Churl Ch. Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. Journal of child and adolescent psychopharmacology. vol 15. issue 2. 2006-01-13. PMID:15910216. |
the results of this study show that, risperidone, a potent combined serotonin (5-ht2) and dopamine (d2) receptor antagonist, is both effective and safe for the treatment for tourette's disorder and chronic tic disorder in children and adolescents. |
2006-01-13 |
2023-08-12 |
human |
| M-B Assié, N Consul-Denjean, W Koek, A Newman-Tancred. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology. vol 75. issue 2. 2005-11-29. PMID:16020947. |
in the striatum, [3h]nemonapride binding was inhibited in a dose-dependent manner with the following order of potency (ed50, mg/kg): nemonapride (0.04), raclopride (0.13), spiperone and risperidone (0.14), haloperidol (0.21), clozapine (7.2) and thioridazine (9.4); in the olfactory lobes: nemonapride (0.03), raclopride and spiperone (0.09), haloperidol (0.10), risperidone (0.15), thioridazine and clozapine (11); in the frontal cortex, only the high affinity dopamine d2 antagonist compounds nemonapride (0.05), haloperidol (0.09), and raclopride (0.12) significantly decreased the binding of [3h]nemonapride. |
2005-11-29 |
2023-08-12 |
rat |
| Marie-Bernadette Assié, Véronique Ravailhe, Valérie Faucillon, Adrian Newman-Tancred. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. The Journal of pharmacology and experimental therapeutics. vol 315. issue 1. 2005-11-28. PMID:15987834. |
in contrast, the increases in dopamine levels induced by clozapine, risperidone, olanzapine, and ziprasidone were not blocked by way100635, consistent with predominant influence of other mechanisms in the actions of these drugs. |
2005-11-28 |
2023-08-12 |
rat |
| Junji Ichikawa, Young-Chul Chung, Jin Dai, Herbert Y Meltze. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain research. vol 1052. issue 1. 2005-10-27. PMID:16061211. |
clozapine and risperidone, as well as the anticonvulsant mood-stabilizers, valproic acid (vpa), zonisamide, and carbamazepine, but not the typical apd haloperidol, increase dopamine (da) release in rat medial prefrontal cortex (mpfc). |
2005-10-27 |
2023-08-12 |
rat |
| Junji Ichikawa, Jin Dai, Herbert Y Meltze. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1A) receptor agonism. Brain research. vol 1049. issue 2. 2005-10-19. PMID:15936730. |
anticonvulsant mood stabilizers, e.g., valproic acid and carbamazepine, and atypical antipsychotic drugs (apds), e.g., clozapine, quetiapine, olanzapine, risperidone, and ziprasidone, have been reported to preferentially increase dopamine (da) release in rat medial prefrontal cortex (mpfc), an effect partially or fully inhibited by way100635, a selective 5-ht(1a) antagonist. |
2005-10-19 |
2023-08-12 |
rat |
| Caroline Fenton, Lesley J Scot. Risperidone: a review of its use in the treatment of bipolar mania. CNS drugs. vol 19. issue 5. 2005-07-27. PMID:15907153. |
risperidone (risperdal) is an atypical antipsychotic with high affinity for 5-hydroxytryptamine (5-ht)2a, dopamine d2 and alpha1- and alpha2-adrenergic receptors. |
2005-07-27 |
2023-08-12 |
Not clear |
| N A Keks, C Culhan. Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert opinion on investigational drugs. vol 8. issue 4. 2005-07-21. PMID:15992090. |
risperidone (risperdal) is a benzisoxazole derivative with a high affinity for serotonin 5-ht2 and dopamine d2 receptors, and some affinity for alpha- adrenergic, histamine h1 and dopamine d1 receptors. |
2005-07-21 |
2023-08-12 |
Not clear |
| Jee-Yeon Kim, In-Kwa Jung, Changsu Han, Sook-Haeng Cho, Leen Kim, Seung-Hyun Kim, Bun-Hee Lee, Heon-Jeong Lee, Yong-Ku Ki. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry and clinical neurosciences. vol 59. issue 2. 2005-05-16. PMID:15823165. |
relatively low doses of risperidone and haloperidol exhibited similar efficacies, and dopamine transporter polymorphisms do not appear to play a major role in the action of antipsychotics on delirium. |
2005-05-16 |
2023-08-12 |
human |
| Gavin P Reynolds, Zhijian Yao, XiaoBin Zhang, Jing Sun, ZhiJun Zhan. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 15. issue 2. 2005-05-03. PMID:15695058. |
we studied the dopamine d3 receptor ser9gly, the dopamine d2 receptor taq ia and the 5-ht2c receptor promoter -759c/t polymorphisms in 117 patients who had symptoms assessed by positive and negative syndrome scale (panss) on admission and following 10-week antipsychotic treatment, primarily with risperidone or chlorpromazine. |
2005-05-03 |
2023-08-12 |
Not clear |
| Michael Soyka, Catja Winter, Sabine Kagerer, Manfred Brunnauer, Gerd Laux, Hans-Jürgen Mölle. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. Journal of psychiatric research. vol 39. issue 1. 2005-04-12. PMID:15504428. |
the present study was designed to evaluate the effects of an atypical neuroleptic (risperidone) in comparison to a conventional dopamine antagonist neuroleptic (haloperidol) on several dimensions of psychomotor performance (visual perception, attention, reaction time, and sensorimotor performance) considered to be of relevance in evaluating driving fitness. |
2005-04-12 |
2023-08-12 |
human |